Adolescent and young adult heroin patients: Drug use and success in methadone maintenance treatment

Journal of Addictive Diseases

Volumn 25, Issue 3, 2006, Pages 15-25

  Kellogg, Scott ^a,b,c   Melia, Dorothy ^a,b   Khuri, Elizabeth ^a,b   Lin, Amy ^a   Ho, Ann ^a   Kreek, Mary Jeanne ^a,b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Addiction treatment; Adolescents; Heroin; Methadone

Indexed keywords

BENZODIAZEPINE; COCAINE; DIAMORPHINE; METHADONE;

ADOLESCENT; ADULT; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DEMOGRAPHY; DRUG USE; ETHNIC DIFFERENCE; FEMALE; HEALTH PROGRAM; HEROIN DEPENDENCE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; RISK ASSESSMENT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; COCAINE-RELATED DISORDERS; DEMOGRAPHY; DRUG INTERACTIONS; FEMALE; HEROIN DEPENDENCE; HUMANS; MALE; METHADONE; NARCOTICS; PATIENT ADMISSION; PATIENT COMPLIANCE; PREVALENCE; RETENTION (PSYCHOLOGY); TOXICOLOGY; TREATMENT OUTCOME;

EID: 33748454266     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1300/J069v25n03_03     Document Type: Article

References (50)

1. Kaminer Y, Tarter RE. Adolescent substance abuse. In: Galanter M, Kleber HD, eds. Textbook of substance abuse, 3rd ed. Washington, DC: Psychiatric Publishing, 2004: 507-517.
2. Brannigan R, Schackman BR, Falco M, Millman RB. The quality of highly regarded adolescent substance abuse treatment programs: Results of an in-depth national survey. Arch Pediatr Adolesc Med. 2004;158: 904-909.
3. National Institute on Drug Abuse. Heroin abuse and addiction. Research report series, NIH publication number 97-4165. Rockville, MD: National Institute on Drug Abuse, 1997.
4. Hopfer CJ, Khuri E, Crowley TJ, Hooks S. Adolescent heroin use: A review of the descriptive and treatment literature. J Subst Abuse Treat. 2002; 23:231-237.
5. SPSS. SPSS for Windows, Rel 10.0 [Computer software]. Chicago, IL: SPSS, Inc., 2000.
6. Hird S, Khuri ET, Dusenbury L, Millman RB. Adolescents. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance abuse: A comprehensive textbook, 3rd ed. Media, PA: Williams & Wilkins, 1997: 683-692.
7. D'Aunno T, Vaugh TE. Variations in methadone treatment practices. Results from a national study. JAMA. 1992; 267:253-258.
8. COMPA. Regarding methadone treatment: A review. New York: Committee of Methadone Program Administrators, Inc, 1995.
9. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Archives of Internal Medicine, 1966; 118: 301-309.
10. Lowinson JH, Payte JT, Salsitz E, Joseph H, Marion IJ, Dole VP. Methadone maintenance. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance abuse: A comprehensive textbook, 3rd ed. Media, PA: Williams & Wilkins, 1997:405-415.
11. Borg L, Broe DM, Ho A, Kreek MJ. Cocaine abuse sharply reduced in an effective methadone maintenance program. J Addict Dis. 1999;18:63-75.
12. Drucker E. From morphine to methadone: Maintenance drugs in the treatment of opiate addiction. In: Harrison LD, Inciardi J, eds. Harm reduction. Thousand Oaks, CA: Sage Publications, 1999:27-45.
13. Des Jarlais DC, Marmor M, Cohen H, Yancovitz S, Garber J, Friedman S, et al. Antibodies to a retrovirus etiologically associated with Acquired Immunodeficiency Syndrome (AIDS) in populations with increased incidences of the syndrome. Morb Mortal. 1984; 33:377-379.
14. Novick DM, Khan I, Kreek MJ. Acquired immunodeficiency syndrome and infection with hepatitis viruses in individuals abusing drugs by injection. United Nations Bull Narc. 1986; 38:15-25.
15. Joseph H, Appel P. Historical perspectives and public health issues. In: Parrino, MW, ed. State methadone treatment guidelines. Center for Substance Abuse Treatment improvement protocol series, vol. 1. Rockville, MD: Center for Substance Abuse Treatment, 1993:11-24.
16. Gunne LM, Gronbladh L. The Swedish methadone program: A controlled study. Drug Alc Depend. 1981; 7:249-256.
17. Zanis DA, Woody GE. One-year mortality rates following methadone treatment discharge. Drug Alcohol Depend. 1998; 52:257-260.
18. Gerstein DR Outcome research: Drug abuse. In Galanter M, Kleber HD (eds.) Textbook of substance abuse treatment, 3rd ed. Washington, DC: American Psychiatric Publishing, 2004; 137-147.
19. Magura S, Nwakeze PC, Demsky S. Pre- and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction. 1998; 93:51-60.
20. Nirenberg TD, Cellucci T, Liepman MR, Swift RM, Sirota AD. Cannabis versus other illicit drug use among methadone maintenance patients. Psych Addic Beh 1996; 10:222-227.
21. Hartel DM, Schoenbaum EE, Selwyn PA, Kline J, Davenny K, Klein RS et al. Heroin use during methadone maintenance treatment: The importance of methadone dose and cocaine use. Am J Public Health. 1995; 85:83-88.
22. Armentano ME, Solhkhah R. Co-occurring disorders in adolescents. In: Graham AW, Schultz TF, Mayo-Smith MF, Ries RK, Wilford BB, (eds.), Principles of addiction medicine. Chevy Chase, MD: American Society of Addiction Medicine, 2003: 1573-1583.
23. Bleich A, Gelkopf M, Schmidt V, Hayward R, Bodner G, Adelson M. Correlates of benzodiazepine abuse in methadone maintenance treatment. A 1 year prospective study in an Israeli clinic. Addiction. 1999; 94:1533-1540.
24. Brehm NM, Khantzian EJ. Psychodynamics. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG (eds.), Substance abuse: A comprehensive textbook, 3rd ed. Media, PA: Williams & Wilkins. 1997; 90-100.
25. Khantzian EJ. The self-medication hypothesis of addictive disorders: Focus on heroin and cocaine dependence. Am J Psychiatry. 1985; 142:1259-1264.
26. Blume AW, Schmaling KB, Marlatt GA. Revisiting the self-medication hypothesis from a behavioral perspective. Cog Behav Prac. 2000; 7:379-384.
27. Del Rio M, Mino A, Perneger TV. Predictors of patient retention in a newly established methadone maintenance treatment programme. Addiction. 1997; 92:1353-1360.
28. Prochaska JO, DiClemente CC, Norcross JC. In search of how people change: Applications to addictive behaviors. Am Psychol. 1992; 47:1102-1114.
29. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci. 1998; 95:9608-9613.
30. LaForge KS, Yuferov V, Kreek MJ. Opioid receptor and peptide gene polymorphisms: Potential implications for addictions. Eur J Pharm. 2000; 410: 249-268.
31. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O'Brien CP. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003; 28:1546-1552.
32. Ebstein RP, Benjamin J, Belmaker RH. Behavioral genetics, genomics, and personality. In: Plomin R, DeFries JC, Craig IW, McGuffin PW (eds.) Behavioral genetics in the postgenomic era. Washington, DC: American Psychological Association, 2003; 365-388.
33. Brooner RK, Kidorf M. Using behavioral reinforcement to improve methadone treatment participation. Sci Prac Persp. 2002; 1:38-47.
34. Marlatt GA, Kilmer JR. Consumer choice: Implications of behavioral economics for drug use and treatment. Beh Ther. 1998; 29:567-576.
35. Adelson MO, Hayward R, Bodner G, Bleich A, Gelkopf M, Kreek MJ. Replication of an effective opiate addiction pharmacotherapeutic treatment model: Minimal need for modification in a different country. J Maint Addict. 2000; 1:5-13.
36. Miller WR, Zweben A, DiClemente CC, Rychtarik RG. Motivational enhancement therapy manual. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism, 1995.
37. Triffleman E, Carroll K, Kellogg S. Substance dependence posttraumatic stress disorder therapy. An integrated cognitive-behavioral approach. J Subst Abuse Treat. 1999; 17:3-14.
38. Ball SA, Young JE. Dual Focus Schema Therapy for personality disorders and substance dependence: Case study results. Cog Behav Prac. 2000; 7:270-281.
39. Calsyn DA, Saxon AJ. An innovative approach to reducing cannabis use in a subset of methadone maintenance clients.Drug Alcohol Depend. 1999; 53:167-169.
40. Kellogg SH, Burns M, Coleman P, Stitzer M, Wale JB, Kreek MJ. Something of value: The introduction of contingency management interventions into the New York City Health and Hospital Addiction Treatment Service. J Subst Abuse Treat. 2005; 28:57-65.
41. Stitzer ML, Iguchi MY, Kidorf M, Bigelow GE. Contingency management in methadone treatment: The case for positive incentives. In: Blaine JD, Boren JJ, Onken LS (eds.), Behavioral treatments for drug abuse and dependence. Rockville, MD: National Institute on Drug Abuse, 1993: 19-35.
42. Petry NM, Martin B, Cooney JL, Kranzler HR. Give them prizes and they will come: Contingency management for treatment of alcohol dependence. J Consult Clin Psychol. 2000; 68:250-257.
43. Higgins ST, Alessi SM, Dantona RL. Voucher-based incentives: A substance abuse treatment innovation. Addict Behav. 2002; 27:887-910.
44. Silverman K, Higgins ST, Brooner RK, Montoya ID, Cone EJ, Schuster CR, Preston KL. Sustained cocaine abstinence in methadone maintenance patients through voucher-based reinforcement therapy. Arch Gen Psychiatry. 1996; 53:409-415.
45. Kellogg S. Identity and recovery. Psychotherapy. 1993; 30:235-244.
46. Jaffe SL. Adolescent treatment and relapse prevention. In Graham WA, Schultz TF, Mayo-Smith MF, Ries RK, Wilford BB (eds.), Principles of addiction medicine. Chevy Chase, MD: American Society of Addiction Medicine, 2003: 1547-1552.
47. Donahue B, Azrin N. Family behavior therapy. In: Wagner ER, Waldon HB (eds.), Innovations in adolescent substance abuse interventions. New York: Pergamon Press, 2001: 205-224.
48. Schwebel R. The Seven Challenges. [On-line] Available: www.sevenchallenges.com, 2003.
49. Kellogg SH, McHugh PF, Bell K, Schluger JH, Schluger RP, LaForge KS, Ho A, Kreek MJ. The Kreek-McHugh-Schluger-Kellogg scale: A new, rapid method for quantifying substance abuse and its possible applications. Drug Alcohol Depend. 2003; 69:137-150.
50. Kreek MJ, Nielsen DA, LaForge KS. Genes associated with addiction: Alcoholism, opiate, and cocaine addiction. Neuromolecular Med. 2004; 5:85-108.